Celgene agreed to invest $100 million in Acetylon Pharmaceuticals in exchange for an exclusive option to purchase the Boston drugmaker at a price that could exceed $1.6 billion contingent on certain milestones. Acetylon will use some of the funding to further develop ACY-1215, its lead drug candidate for myeloma. Celgene took a $15 million equity stake in Acetylon last year.

Related Summaries